{"schema_version":"secwatch.filing_event.v1","accession":"0001827635-26-000010","form_type":"8-K","ticker":"MANE","cik":"0001827635","company_name":"Veradermics, Inc","filed_at":"2026-03-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.393114+00:00","generated_at":"2026-05-15T08:25:55.415471+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Veradermics reports FY 2025 net loss $70M; cash $141.9M; IPO raised $295M; two pivotal trials enrolled","bullets":["FY 2025 net loss $70.0M vs $26.5M in 2024; Q4 net loss $21.8M vs $5.7M.","Cash, equivalents & marketable securities $141.9M at Dec 31, 2025; upsized IPO added $294.8M gross in Feb 2026.","R&D expenses FY 2025 $62.1M (up $38.8M YoY) driven by VDPHL01 clinical development and headcount.","Enrollment completed in Phase 2/3 Study 302 (male PHL) and confirmatory Study 304; topline data 1H and 2H 2026.","Appointed Mark Neumann as Chief Commercial & Strategy Officer; Study 306 enrolling for female PHL."],"urls":{"canonical":"https://secwatch.observer/filing/0001827635-26-000010","json":"https://secwatch.observer/filing/0001827635-26-000010.json","markdown":"https://secwatch.observer/filing/0001827635-26-000010.md","text":"https://secwatch.observer/filing/0001827635-26-000010.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1827635/000182763526000010/0001827635-26-000010-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1827635/000182763526000010/mane-20260330.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T08:25:55.415471+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"745cca53780c3ea1d7bc0bbb75e6270f1bbe6926","claim":"Veradermics, Inc reported financial results for the fourth quarter and year ended December 31, 2025.","evidence_excerpt":"On March 30, 2026, Veradermics, Incorporated issued a press release announcing its financial results for the fourth quarter and year ended December 31, 2025.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1827635/000182763526000010/0001827635-26-000010-index.htm","confidence":0.7,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and year ended December 31, 2025"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}